Emrullah Yilmaz
Hematology & Oncology · Albuquerque, NMNPI 1972824084
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,400 of the $3,735 with a category attached, or 91.0%. Astellas Pharma Global Development accounts for 91.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $3,544 and has fallen 96.2% since, to $136 in 2023.
Across 4 payments — averaging $933.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$3K
- Tactile Systems Technology Inc$144
- Foundation Medicine, Inc.$136
- Regeneron$55
Across 29 payments — averaging $45,524 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.3M
- Regeneron$22K
- Pfizer$17K
- Astellas Pharma Global Development$1K
What the payments were for
- Consulting fees$3,40091%
- Food & beverage$3359%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 1 | $3,400 |
| Tactile Systems Technology Inc | 1 | $144 |
| Foundation Medicine, Inc. | 1 | $136 |
| Regeneron | 1 | $55 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PADCEV$3,400
- Flexitouch Plus$144
- ENTRE$144
- FOUNDATIONONE CDX$136
How this compares
$3,735 in reported general payments places this provider in the 60th percentile of 54 hematology & oncology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Monohydrate | 18 | $1,267 |
| Levothyroxine Sodium | 15 | $282 |
| Prochlorperazine Maleate | 15 | $227 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Albuquerque
- Ursa Brown GlabermanAlbuquerque$219K
- Neda Hashemi SadraeiAlbuquerque$96K
- Muhammad TarakjiAlbuquerque$34K
- Yara AbdouAlbuquerque$25K
- George AtwehAlbuquerque$24K
- Scott HerbertAlbuquerque$14K
- Jose AvitiaAlbuquerque$11K
- Zoneddy DayaoAlbuquerque$10K
- Toufic TannousAlbuquerque$10K
- Amy TarnowerAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.